Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis

Immunology

Volumn 142, Issue 3, 2014, Pages 431-441

  Fransson, Moa ^a   Piras, Elena ^a   Wang, Hao ^a   Burman, Joachim ^a,b   Duprez, Ida ^a   Harris, Robert A ^c   Leblanc, Katarina ^c,d   Magnusson, Peetra U ^a   Brittebo, Eva ^a   Loskog, Angelica S I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chimeric antigen receptor; Experimental autoimmune encephalitis; Gene engineering; Mesenchymal stromal cells; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ARTICLE; ASTROCYTOSIS; CELL ENGINEERING; CELL EXPANSION; CEREBELLUM; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; DRUG DELIVERY SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HIPPOCAMPUS; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MESENCHYMAL STROMA CELL; MOUSE; MYELINATION; NONHUMAN; OLFACTORY BULB; OLFACTORY NUCLEUS; ORBITAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURKINJE CELL; SEPTUM NUCLEUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; THALAMUS NUCLEUS; THERAPY EFFECT; TISSUE DISTRIBUTION;

CHIMERIC ANTIGEN RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS; GENE ENGINEERING; MESENCHYMAL STROMAL CELLS; MULTIPLE SCLEROSIS;

ADMINISTRATION, INTRANASAL; ANIMALS; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETIC ENGINEERING; HUMANS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 84901997414     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12275     Document Type: Article

References (52)

1. Bernado ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant 2012; 47:164-71.
2. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
3. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006; 13:419-25.
4. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36:2566-73.
5. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11-20.
6. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-22.
7. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105:2214-9.
8. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-8.
9. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305:33-41.
10. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35:1482-90.
11. + regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92:881-8.
12. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001; 189:49-57.
13. Li Y, Chen J, Chen XG et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002; 59:514-23.
14. Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells efficiently modulate pathogenic immune response in experimental autoimmune encephalomyelitits. Ann Neurol 2007; 61:219-27.
15. Zhang J, Li Y, Chen J et al. Human bone marrow stromal cell treatments improves neurological functional recovery in EAE mice. Exp Neurol 2005; 195:16-26.
16. Chopp M, Zhang XH, Li Y et al. Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. NeuroReport 2000; 11:3001-5.
17. Schwarz EJ, Alexander GM, Prockop DJ, Azizi SA. Multipotential marrow stromal cells transduced to produce l-DOPA: engraftment in a rat model of Parkinson disease. Hum Gene Ther 1999; 10:2539-49.
18. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007; 28:219-26.
19. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-41.
20. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28:1446-55.
21. Kassis I, Grigoriadis N, Gowda-Kurkalli B et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008; 65:753-61.
22. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4:50-7.
23. Yamout B, Hourani R, Salti H et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 2010; 227:185-9.
24. Karussis D, Karageorgiou C, Vaknin-Dembinsky A et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67:1187-94.
25. Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 2010; 41:129-37.
26. Bai L, Lennon DP, Eaton V et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57:1192-203.
27. Uccelli A, Prockop DJ. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 2010; 22:768-74.
28. Wang Y, Xu F, Zhang C et al. High MR sensitive fluorescent magnetite nanocluster for stem cell tracking in ischemic mouse brain. Nanomedicine 2011; 7:1009-19.
29. Gordon D, Pavlovska G, Glover CP, Uney JB, Wraith D, Scolding NJ. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008; 448:71-3.
30. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, Jacob U. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci USA 2003; 100:9446-51.
31. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003; 5:211-26.
32. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29:550-7.
33. Fransson M, Piras E, Burman J et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation 2012; 9:112.
34. Meisel R, Brockers S, Heseler K et al. Human but not murine multipotent mesenchymal stromal cells exhibit antimicrobial effector function mediated by indoleamine 2, 3-dioxygenase. Leukemia 2011; 25:648-54.
35. Johansson U, Rasmusson I, Niclou SP et al. Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revasularization. Diabetes 2008; 57:2393-401.
36. Jiang Y, Zhu J, Xu G, Liu X. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011; 8:623-32.
37. Danielyan L, Schäfer R, von Ameln-Mayerhofer A et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009; 88:315-24.
38. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 2010; 68:419-22.
39. Danielyan L, Schäfer R, von Ameln-Mayerhofer A et al. Therputic efficacy of intranasally delivered mesenchymal stromal cells in a rat model of Parkinson's disease. Rejuvenation Res 2011; 1:3-16.
40. Hou Y, Ryo CH, Park KY, Kim SM, Jeong CH, Jeun SS. Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice. Stem Cell Res 2013; 4:77.
41. Englund U, Björklund A, Wictorin K. Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res Dev Brain Res 2002; 134:123-41.
42. Nern C, Wolff I, Macas J et al. Fusion of hematopoietic cells with Purkinje neurons does not lead to stable heterokaryon formation under noninvasive conditions. J Neurosci 2009; 29:3799-807.
43. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003; 425:968-73.
44. Kemp K, Gordon D, Wraith DC et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells. Neuropathol Appl Neurobiol 2010; 37:166-78.
45. Iglesias D, El-Kares R, Taranta A et al. Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS ONE 2012; 7:e42840.
46. Westin U, Piras E, Jansson B et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005; 24:565-73.
47. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11:1-18.
48. Matsushita T, Kibayashi T, Katayama T et al. Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett 2011; 502:41-5.
49. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999; 96:10711-6.
50. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25:371-9.
51. Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67:9142-9.
52. Pockop DJ, Brenner M, Fibbe WE et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12:576-8.